A device for dried blood microsampling in quantitative bioanalysis Methodology
1.300 1.200 1.100 1.000 0.900 0.800 0.700 0.600
020406080 Hematocrit (%)
Figure 3. Variation in the density of blood with hematocrit determined by each of the six participating laboratories. Laboratories 1, 2, 3 and 6 used human blood while laboratories 4 and 5 used rat blood. Comparisons to published values for human blood density are also illustrated [27]. Each data point is the average of six determinations made at each laboratory.
variations in the volume of blood analyzed with dif- ferent HCTs when using DBS sampling are mini- mized or eliminated with the novel VAMS. While
the VAMS device demonstrates much
promise for the accurate collection of small blood volumes for quantitative bioanalysis and overcomes a number of issues associated with DBS sampling, further investigation is required in order to demon- strate its quantitative bioanalytical performance and practical use in busy clinical and laboratory settings. As such, a number of other characterizations of the VAMS for drug concentration measurement have been undertaken and will be reported in separate publications.
Future perspective Further thorough investigations in order to fully understand the reality of the benefits and any possible issues associated with the bioanalytical and practical field performance of the VAMS device are required before its widespread practical application and regu- latory acceptance is realized. If successful, the VAMS has the potential to deliver simplified blood collec- tion, shipping, storage and analytical approaches for the quantitative bioanalysis of pharmaceuticals and biomarkers compared with currently accepted wet and dry processes. In particular, it is likely that the device will see rapid adoption for the collection of high-quality samples that are problematic for cur- rent processes (i.e., pediatric studies, subjects in
future science group
remote geographic locations, home sampling or serial sampling from rodent studies).
Acknowledgements Janssen would like to thank D Van Roosbroek. BMS would like to thank S Basdeo, C D’Arienzo, L Discenza and T Olah. Merck would like to thank I Xie, L Xue and M Wang. The Neoteryx and Phenomenex authors would like to formally acknowl- edge GlaxoSmithkline’s N Spooner and P Dennif for their sig- nificant contribution and support in the development of the volumetric absorbtive microsampler technology. The authors would like to formally acknowledge the scientific contribu- tions of our colleagues in this pilot study who were involved in the development of the volumetric absorbtive microsampler technology and the Mitra™ microsampling device.
Financial & competing interests disclosure Financial support for this work was provided by Neoteryx and Phenomenex. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this
manuscript.
Open access This work is licensed under the Creative Commons Attribution- NonCommercial 3.0 Unported License. To view a copy of this license, visit
http://creativecommons.org/licenses/by-nc-nd/3.0/
www.future-science.com 657
Laboratory 1 Laboratory 2
Laboratory 3(1) Laboratory 3(2)
Laboratory 4 Laboratory 5 Laboratory 6
Average Published
Blood density (g/ml)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154